title: [Comparison of endocrine therapy and chemotherapy for bone metastasis of breast cancer].
abstract: OBJECTIVE
  To compare the efficacy of endocrine therapy with chemotherapy for bone metastasis of breast cancer.
  
  
  METHODS
  A total of 138 breast cancer patients with bone metastasis, but without visceral metastasis as retrospectively reviewed.
  
  
  RESULTS
  The response rates of endocrine therapy and chemotherapy as the first-line therapy were 35.4% and 31.7% (P = 0.687), and the total response rates were 27.1% and 25.0% (P = 0.690). The clinical benefit rates of endocrine therapy and chemotherapy as first-line were 43.9% and 36.6% (P = 0.437), as second-line were 47.8% and 24.2% (P = 0.033), in total treatments were 47.5% and 27.7% (P = 0.001). The median interval to treatment failure (TTF) was 5 months and 2 months (P < 0.001), and that to progression (TTP) was 5 and 2.5 months (P < 0.001) in endocrine therapy and chemotherapy group, respectively.
  
  
  CONCLUSIONS
  Endocrine therapy is superior to chemotherapy for bone metastasis of breast cancer.
authors.affiliation: Department of Breast Cancer, No.307 Hospital, Academy of Military Medical Sciences, Beijing 100039, China.
authors.forename: Min
authors.initials: M
authors.lastname: Yan
authors.forename: San-Tai
authors.initials: ST
authors.lastname: Song
authors.forename: Ze-Fei
authors.initials: ZF
authors.lastname: Jiang
authors.forename: Shao-Hua
authors.initials: SH
authors.lastname: Zhang
authors.forename: Xiao-Qing
authors.initials: XQ
authors.lastname: Liu
authors.forename: Jian-Ming
authors.initials: JM
authors.lastname: Xu
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Luo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy; D001943:Breast Neoplasms / Q000401:mortality / Q000628:therapy*; D005260:Female; D006801:Humans; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents